GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus

被引：13
|
作者：
Al-Jaber, Hend [1 ]
Al-Mansoori, Layla [1 ]
Elrayess, Mohamed A. [1 ]
机构：
[1] Qatar Univ, Biomed Res Ctr, Doha, Qatar
来源：
CURRENT DIABETES REVIEWS | 2021年 / 17卷 / 02期
关键词：
GATA-3; therapeutic target; insulin resistance; adipogenesis; inflammation; type; 2; diabetes; TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE INFLAMMATION; HUMAN SUBCUTANEOUS ADIPOGENESIS; REGULATORY T-CELLS; TRANSCRIPTION FACTORS; METABOLICALLY HEALTHY; FACTOR-ALPHA; INHIBITS ADIPOGENESIS; IMPAIRED ADIPOGENESIS; LINKING OBESITY;
D O I：
10.2174/1573399816666200705210417
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Impaired adipogenesis plays an important role in the development of obesity-associated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition. The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation is a crucial mediator of this process. Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA-3, causing exacerbation of the inflammatory state associated with obesity. This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and amelioration of the immune response.
引用
收藏
页码：169 / 179
页数：11
相关论文
共 50 条
  • [41] Glucagon antagonism as a potential therapeutic target in type 2 diabetes
    Bagger, J. I.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    DIABETES OBESITY & METABOLISM, 2011, 13 (11): : 965 - 971
  • [42] Diabetes: Dapagliflozin: An insulin-independent, therapeutic option for type 2 diabetes mellitus
    Wilson C.
    Nature Reviews Endocrinology, 2010, 6 (10) : 531 - 531
  • [43] Insulin Resistance in Type 2 Diabetes Mellitus: Prospect of an Untouched Area
    Singh, Sandeep
    Jain, Maneesh
    Singh, Ajaypal
    Multani, Manish Kishore
    Purohit, Ashish
    DIABETES, 2013, 62 : A692 - A692
  • [44] Basal Insulin Resistance and Secretion in Nigerians With Type 2 Diabetes Mellitus
    Oli, J. M.
    Adeyemo, A. A.
    Okafor, G. O.
    Ofoegbu, E. N.
    Onyenekwe, B.
    Chukwuka, C. J.
    Onwasigwe, C. N.
    Ufelle, S.
    Chen, G.
    Rotimi, C. N.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2009, 7 (06) : 595 - 599
  • [45] Investigating for Insulin Resistance and Type 2 Diabetes Mellitus in Obese Children
    Simsek, Enver
    Karabay, Meltem
    Aras, Sukru
    Kocabay, Kenan
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2005, 9 (01) : 17 - 22
  • [46] VLDL secretion and catabolism in insulin resistance and type 2 diabetes mellitus
    Hernandez-Ono, A.
    Moon, B.
    Zhang, Y. -L.
    Ginsberg, H. N.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 15 - 16
  • [47] Insulin Resistance and Type 2 Diabetes Mellitus: An Ultimatum to Renal Physiology
    Sinha, Susmita
    Haque, Mainul
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [48] Migratory ichthyosiform dermatosis with type 2 diabetes mellitus and insulin resistance
    Yosipovitch, G
    Mevorah, B
    David, M
    Feinmesser, M
    Hodak, E
    Gabay, B
    Ammash, J
    Elias, PM
    ARCHIVES OF DERMATOLOGY, 1999, 135 (10) : 1237 - 1242
  • [49] Unraveling the Gordian knot of insulin resistance in type 2 diabetes mellitus
    Weijers, Rob N. M.
    AIMS MEDICAL SCIENCE, 2022, 9 (03): : 424 - 432
  • [50] Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management
    Kernan W.N.
    Inzucchi S.E.
    Current Treatment Options in Neurology, 2004, 6 (6) : 443 - 450
12345